PRELIMINARY STUDY: Noncompliance is the leading cause of nonresponse to drug. This 1-year preliminary study randomly assigns 80 outpatients with alcohol dependence to 2 strategies for monitoring compliance (Medication Event Monitoring System [MEMS] vs. blister pack) in relation to plasma levels of naltrexone and 6-beta-naltrexol, and to 2 strategies for enhancing compliance (compliance counseling vs. usual care) in a 2X2 design. All subjects receive 8 weeks of Medication Management Therapy (MMT) and naltrexone to assess acceptability and rate of compliance with the dosing regimen and minimally intensive therapy condition proposed for the main study. MAIN STUDY: New advances in outpatient pharmacologic and behavioral treatments of alcohol dependence have generally occurred independently of each other. The objective of the main study is to evaluate the relative efficacy of combined treatments in a 2X4 multicenter, double-blind, randomized, placebo-controlled comparison of 4 pharmacotherapy conditions (acamprosate, naltrexone, placebo, and acamprosate/naltrexone in combination) administered in conjunction with either the cognitive behavioral therapy typically administered by an alcoholism treatment specialist, or a manualized MMT that may be suitable for managed care settings. Primary outcome measures are time to first drink, time to first heavy drinking day, and cumulative abstinence duration. Treatment duration is 6 months with 1 year of posttreatment follow-up. Subjects for the multicenter study are 1200 outpatients meeting DSM IV criteria for alcohol dependence, recruited across 6-8 centers. NONRESPONDER STUDY: A response evaluation will be made at 3 months post-randomization in the main study. Approximately 400 nonresponders to active medication will be available for a 12-week comparison of alternative pharmacotherapy strategies commonly used in general clinical practice. All other subjects will remain in the originally assigned treatment condition in the main study. Nonresponders to monotherapy will be randomized to the alternative monotherapy or combination treatment, nonresponders to combination treatment will be randomized to increased doses of acamprosate or naltrexone.

National Institute of Health (NIH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZAA1-EE (01))
Program Officer
Fuller, Richard K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Miami School of Medicine
Schools of Medicine
United States
Zip Code
Doyle, Suzanne R; Donovan, Dennis M; Simpson, Tracy L (2011) Validation of a nine-dimensional measure of drinking motives for use in clinical applications: the desired effects of drinking scale. Addict Behav 36:1052-60
Oroszi, Gabor; Anton, Raymond F; O'Malley, Stephanie et al. (2009) OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 33:383-93
Doyle, Suzanne R; Donovan, Dennis M (2009) A validation study of the alcohol dependence scale. J Stud Alcohol Drugs 70:689-99
Ray, Lara A; Oslin, David W (2009) Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. Drug Alcohol Depend 105:256-8
Anton, Raymond F; Oroszi, Gabor; O'Malley, Stephanie et al. (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65:135-44
Donovan, Dennis M; Anton, Raymond F; Miller, William R et al. (2008) Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. J Stud Alcohol Drugs 69:5-13
Doyle, Suzanne R; Donovan, Dennis M; Kivlahan, Daniel R (2007) The factor structure of the Alcohol Use Disorders Identification Test (AUDIT). J Stud Alcohol Drugs 68:474-9
Donovan, Dennis M; Kivlahan, Daniel R; Doyle, Suzanne R et al. (2006) Concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) and AUDIT zones in defining levels of severity among out-patients with alcohol dependence in the COMBINE study. Addiction 101:1696-704
Anton, Raymond F; Youngblood, Marston (2006) Factors affecting %CDT status at entry into a multisite clinical treatment trial: experience from the COMBINE Study. Alcohol Clin Exp Res 30:1878-83
Youngblood, Marston E; Murray, Kelly T; Devine, Eric et al. (2005) Coordinating and monitoring multisite clinical trials that combine pharmacological and behavioral treatments. J Stud Alcohol Suppl :82-91; discussion 65

Showing the most recent 10 out of 15 publications